Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2022 Jul 11

PMID 35813376

Authors

Shang Mengxuan

Zhou Fen

Jin Runming

Affiliations

Soon will be listed here.

Abstract

With the markedly increased cure rate for children with newly diagnosed pediatric B-cell acute lymphoblastic leukemia (B-ALL), relapse and refractory B-ALL (R/R B-ALL) remain the primary cause of death worldwide due to the limitations of multidrug chemotherapy. As we now have a more profound understanding of R/R ALL, including the mechanism of recurrence and drug resistance, prognostic indicators, genotypic changes and so on, we can use newly emerging technologies to identify operational molecular targets and find sensitive drugs for individualized treatment. In addition, more promising and innovative immunotherapies and molecular targeted drugs that are expected to kill leukemic cells more effectively while maintaining low toxicity to achieve minimal residual disease (MRD) negativity and better bridge hematopoietic stem cell transplantation (HSCT) have also been widely developed. To date, the prognosis of pediatric patients with R/R B-ALL has been enhanced markedly thanks to the development of novel drugs. This article reviews the new advancements of several promising strategies for pediatric R/R B-ALL.

Citing Articles

Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy.

Johns C, Erickson C, Jacobs A, Moon J, Baggott C, Dagher R Front Immunol. 2024; 15:1423487.

PMID: 39386214 PMC: 11461246. DOI: 10.3389/fimmu.2024.1423487.

Liposomal mitoxantrone-based multidrug chemotherapy as a bridge to allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute lymphoblastic leukemia (ALL) after immunotherapy failure: a case report.

Deng J, Chen H, Yang Y, Ji H, Liu H Front Med (Lausanne). 2024; 11:1383288.

PMID: 38854665 PMC: 11161177. DOI: 10.3389/fmed.2024.1383288.

Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.

Willyanto S, Alimsjah Y, Tanjaya K, Tuekprakhon A, Pawestri A Ann Med. 2024; 56(1):2349796.

PMID: 38738799 PMC: 11095278. DOI: 10.1080/07853890.2024.2349796.

gene polymorphism and pediatric acute lymphoblastic leukemia relapse susceptibility among Chinese children: a five-center case-control study.

Ding W, Wang D, Cai M, Yan Y, Liu S, Liu X Front Oncol. 2023; 13:1203002.

PMID: 38023199 PMC: 10652278. DOI: 10.3389/fonc.2023.1203002.

Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia.

Ruiz-Ciancio D, Lin L, Veeramani S, Barros M, Sanchez D, Di Bartolo A Mol Ther Nucleic Acids. 2023; 33:698-712.

PMID: 37662970 PMC: 10469072. DOI: 10.1016/j.omtn.2023.07.028.

References

Wyatt K, Bram R . Immunotherapy in pediatric B-cell acute lymphoblastic leukemia. Hum Immunol. 2019; 80(6):400-408. DOI: 10.1016/j.humimm.2019.01.011. View

Malempati S, Gaynon P, Sather H, La M, Stork L . Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. J Clin Oncol. 2007; 25(36):5800-7. DOI: 10.1200/JCO.2007.10.7508. View

Liu L, Jiao W, Zhang Y, Qu Q, Li X, Wu D . Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute.... Leuk Res. 2015; 39(3):323-8. DOI: 10.1016/j.leukres.2015.01.003. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris M . Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011; 118(25):6521-8. DOI: 10.1182/blood-2011-05-351403. View

Tsujimoto Y, Croce C . Recent progress on the human bcl-2 gene involved in follicular lymphoma: characterization of the protein products. Curr Top Microbiol Immunol. 1988; 141:337-40. DOI: 10.1007/978-3-642-74006-0_45. View

Guedan S, Calderon H, Posey Jr A, Maus M . Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019; 12:145-156. PMC: 6330382. DOI: 10.1016/j.omtm.2018.12.009. View

Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C . Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia. 2008; 22(12):2193-200. DOI: 10.1038/leu.2008.227. View

Wolach O, Stone R . Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015; 21(19):4262-9. DOI: 10.1158/1078-0432.CCR-15-0125. View

10.

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

11.

Andersson E, Putzer S, Yadav B, Dufva O, Khan S, He L . Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia. 2017; 32(3):774-787. DOI: 10.1038/leu.2017.252. View

12.

Ford A, Mansur M, Furness C, van Delft F, Okamura J, Suzuki T . Protracted dormancy of pre-leukemic stem cells. Leukemia. 2015; 29(11):2202-7. PMC: 4564945. DOI: 10.1038/leu.2015.132. View

13.

Kurtz S, Eide C, Kaempf A, Khanna V, Savage S, Rofelty A . Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A. 2017; 114(36):E7554-E7563. PMC: 5594650. DOI: 10.1073/pnas.1703094114. View

14.

Johansson B, Fioretos T, Mitelman F . Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002; 107(2):76-94. DOI: 10.1159/000046636. View

15.

Verstovsek S, Odenike O, Singer J, Granston T, Al-Fayoumi S, Deeg H . Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016; 9(1):137. PMC: 5146859. DOI: 10.1186/s13045-016-0367-x. View

16.

Rozenbaum M, Meir A, Aharony Y, Itzhaki O, Schachter J, Bank I . Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia. Front Immunol. 2020; 11:1347. PMC: 7343910. DOI: 10.3389/fimmu.2020.01347. View

17.

Mueller-Schoell A, Groenland S, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R . Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2020; 77(4):441-464. PMC: 7935845. DOI: 10.1007/s00228-020-03014-8. View

18.

Freyer D, Devidas M, La M, Carroll W, Gaynon P, Hunger S . Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood. 2011; 117(11):3010-5. PMC: 3062307. DOI: 10.1182/blood-2010-07-294678. View

19.

Tran T, Hunger S . The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities. Semin Cancer Biol. 2020; 84:144-152. DOI: 10.1016/j.semcancer.2020.10.013. View

20.

OBrien M, Ji L, Shah N, Rheingold S, Bhojwani D, Yuan C . Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022; 40(9):956-967. PMC: 8937013. DOI: 10.1200/JCO.21.01693. View